PURPLE BIOTECH LTD-ADR(NASDAQ:PPBT) stock News

PPBT Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Purple Biotech Ltd.

Purple Biotech Reports Second Quarter 2025 Financial Results

a month ago - By: Purple Biotech Ltd.

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

a month ago - By: Purple Biotech Ltd.

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

2 months ago - By: Purple Biotech Ltd.

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

9 months ago - By: Benzinga

Why Purple Biotech (PPBT) Stock Is Getting Hammered

2 months ago - By: Purple Biotech Ltd.

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

2 months ago - By: Benzinga - Mentions: LIXT ATRA MODV IMRX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

3 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

3 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

3 months ago - By: Purple Biotech Ltd.

Purple Biotech Reports First Quarter 2025 Financial Results

3 months ago - By: Purple Biotech Ltd.

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

3 months ago - By: Purple Biotech Ltd.

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

4 months ago - By: Purple Biotech Ltd.

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

4 months ago - By: Purple Biotech Ltd.

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

4 months ago - By: Purple Biotech Ltd.

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

4 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer

4 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer

5 months ago - By: Purple Biotech Ltd.

Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025

5 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

5 months ago - By: Purple Biotech Ltd.

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

5 months ago - By: Purple Biotech Ltd.

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

6 months ago - By: Purple Biotech Ltd.

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

6 months ago - By: Purple Biotech Ltd.

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

6 months ago - By: Purple Biotech Ltd.

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

6 months ago - By: Purple Biotech Ltd.